Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) and Its Officers for Potential Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for potential securities law violations after the company announced the discontinuation of its pociredir program for sickle cell disease. The decision followed heightened FDA concerns regarding the drug's benefit-risk profile due to malignancy risks associated with its mechanism of action, leading to a significant drop in Fulcrum Therapeutics' stock price. The law firm is seeking investors who suffered losses to provide information for their investigation.
Kaplan Fox Announces an Investigation of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) on Behalf of Long-Term Investors
Kaplan Fox & Kilsheimer LLP has announced an investigation into potential securities violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following the discontinuation of its pociredir program for sickle cell disease. The decision came after the FDA raised concerns about the drug's benefit-risk profile due to observed secondary hematologic malignancies, leading to a 51.09% drop in stock price. The firm is seeking investors who suffered losses to assist with the investigation.
Kaplan Fox Reminds Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors of an Ongoing Securities Law Investigation
Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program for sickle cell disease. This decision followed heightened FDA concerns regarding the drug's benefit-risk profile due to an unexpectedly high rate of secondary hematologic malignancies observed with another PRC2 inhibitor. Following this news, Fulcrum Therapeutics' stock price declined by over 51%.
Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors of an Investigation Into Possible Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. following a significant stock decline. The investigation stems from Fulcrum's announcement on June 1, 2026, to discontinue its pociredir program for sickle cell disease after the FDA raised concerns about the drug's benefit-risk profile due to potential malignancy risks associated with PRC2 inhibitors. This news led to a 51.09% drop in Fulcrum's stock price.
Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Fulcrum Therapeutics (FULC) has experienced a significant 51% stock decline over the past four weeks, placing it in oversold territory. Despite this, a potential trend reversal is indicated by its Relative Strength Index (RSI) of 21.62 and a 30% increase in consensus EPS estimates from Wall Street analysts over the last 30 days. The stock currently holds a Zacks Rank #2 (Buy), suggesting a strong possibility for a near-term turnaround.
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the merger between Fulcrum Therapeutics, Inc. (NASDAQ: FULC) and Slate Medicines, Inc. The investigation focuses on whether Fulcrum shareholders are receiving a fair price, whether the sales process was free of conflicts of interest, and if all material information was disclosed. Upon closing, Fulcrum shareholders are expected to own 5.0% of the combined company.
Kaplan Fox Launches Investigation Into Fulcrum Therapeutics Following 51% Stock Plunge After Pociredir Program Halt
Kaplan Fox & Kilsheimer LLP has initiated an investigation into Fulcrum Therapeutics, Inc. (NASDAQ:FULC) for potential securities law violations. This comes after Fulcrum announced on June 1, 2026, that it would discontinue its pociredir program for sickle cell disease due to significant FDA concerns regarding the drug's benefit-risk profile, leading to a 51.09% stock plunge. The FDA's decision was influenced by similar malignancy risks associated with another PRC2 inhibitor, Tazverik, which was globally withdrawn.
Kaplan Fox Investigates Fulcrum Therapeutics After Pociredir Discontinuation Triggers 51% Stock Collapse
Kaplan Fox & Kilsheimer LLP has launched an investigation into Fulcrum Therapeutics (NASDAQ: FULC) for potential securities law violations. This follows Fulcrum's decision on June 1, 2026, to discontinue its pociredir program for sickle cell disease due to FDA concerns over its benefit-risk profile, which led to a 51.09% stock drop. The FDA's concerns arose from observed secondary hematologic malignancies with another PRC2 inhibitor, Tazverik®, suggesting similar risks for pociredir and leaving no clear regulatory path.
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Possible Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program for sickle cell disease. This decision followed FDA concerns regarding the drug's benefit-risk profile, particularly an unexpectedly high rate of secondary hematologic malignancies observed with a similar drug. The news led to a significant 51.09% decline in Fulcrum Therapeutics' stock price.
Kaplan Fox Launches Securities Investigation Into Fulcrum Therapeutics After 51% Stock Collapse
Law firm Kaplan Fox & Kilsheimer LLP has initiated a securities investigation into Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following a 51.09% stock drop. This probe comes after Fulcrum announced the discontinuation of its sickle cell disease program for pociredir due to FDA concerns over malignancy risks associated with PRC2 inhibitors. Investors who experienced losses are encouraged to contact the firm regarding potential securities violations.
Former Fulcrum Therapeutics (FULC) officer moves to sell about $54K in stock
A former officer of Fulcrum Therapeutics (FULC), Greg Tourangeau, has filed a Rule 144 notice indicating a planned sale of 14,062 shares of company common stock, valued at approximately $54,419.94 as of September 2, 2026. These shares originated from various equity awards and programs between 2018 and 2025. The filing shows Merrill Lynch, Pierce, Fenner & Smith Inc. as the broker for the potential sale.
Kaplan Fox is Investigating Possible Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program for sickle cell disease. This decision followed FDA concerns about the drug's safety profile, leading to a significant 51.09% drop in Fulcrum Therapeutics' stock price. The firm is seeking investors who suffered losses or have information relevant to the investigation.
Kaplan Fox Announces an Investigation of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) on Behalf of Investors
Kaplan Fox & Kilsheimer LLP has initiated an investigation into potential securities violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following a significant drop in its stock price. This investigation stems from Fulcrum's announcement to discontinue its pociredir program for sickle cell disease due to FDA concerns regarding the malignancy risk associated with its PRC2 inhibitor. Investors who suffered losses are encouraged to contact Kaplan Fox.
Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough?
Fulcrum Therapeutics (FULC) is undergoing an all-stock merger with Slate Medicines, transforming into a migraine-focused biotechnology company. The deal involves Slate holders owning 55.9%, PIPE investors 39.1%, and legacy Fulcrum holders 5% of the combined entity, with Fulcrum distributing an estimated $270 million cash dividend ($3.54/share). This transaction effectively offers Fulcrum shareholders a cash payout plus a small stake in Slate's migraine pipeline, which currently lacks human efficacy data.
Fulcrum Therapeutics stock plunges 51% after halting sickle cell drug due to FDA safety concerns
Fulcrum Therapeutics' stock plummeted 51% after the company discontinued its sickle cell disease drug, pociredir, due to FDA safety concerns about a high rate of secondary blood cancers. This decision eliminated any viable regulatory path for the drug's development. Kaplan Fox & Kilsheimer LLP is now investigating potential securities violations, highlighting the significant regulatory risks in drug development for rare diseases.
Slate uses Fulcrum to join Nasdaq with $245M for migraine trials
Slate Medicines is set to list on Nasdaq through a reverse merger with Fulcrum Therapeutics, securing $245 million for migraine trials. The company's lead candidate, SLTE-1009, a monoclonal antibody targeting PACAP and VIP, is expected to have topline safety and pharmacokinetic data in mid-2027, with a phase 2 study planned for the second half of next year. This funding is projected to provide a runway into 2029, also supporting the development of a second candidate, SLTE-2100.
Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc. - FULC
Kahn Swick & Foti, LLC (KSF) is investigating the proposed merger of Fulcrum Therapeutics, Inc. (NasdaqGM: FULC) and Slate Medicines, Inc. The law firm is examining whether the merger and its process are fair to Fulcrum shareholders, who are expected to own 5.0% of the combined company. Shareholders are encouraged to contact KSF for legal consultation regarding their rights.
Slate Medicines to Merge With Fulcrum Therapeutics
Cooley advised Slate Medicines on its definitive agreement to combine with Fulcrum Therapeutics in an all-stock reverse merger. The combined company will operate as Slate Medicines, Inc. and is expected to trade on Nasdaq under "SLTE." In conjunction with the merger, Cooley also advised Slate on an oversubscribed concurrent private placement financing of $245 million.
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm Regarding an Investigation Into Possible Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following a significant drop in its stock price. The decline occurred after the company announced the discontinuation of its pociredir program for sickle cell disease due to FDA concerns about malignancy risks associated with PRC2 inhibitors. Investors who suffered losses are encouraged to contact Kaplan Fox for more information regarding this investigation.
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm Regarding an Investigation Into Possible Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company discontinued its pociredir program due to FDA concerns about an unexpectedly high rate of secondary hematologic malignancies. This announcement led to a significant 51.09% drop in Fulcrum Therapeutics' stock price. The firm is encouraging investors who have suffered losses or have relevant information to contact them regarding this investigation.
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Fulcrum Therapeutics (Nasdaq: FULC) regarding potential breaches of fiduciary duty related to its transaction with Slate Medicines. The investigation focuses on whether Fulcrum's public shareholders are receiving a fair price, given that they are expected to own only 5.0% of the combined company while Slate shareholders will own 95.0%. The firm is also scrutinizing the board's conduct and the transaction's terms, including a significant penalty for accepting competing bids.
Latham Advises Frazier Life Sciences on Private Placement Financing With Fulcrum Slate Merger
Latham & Watkins LLP advised Frazier Life Sciences on an oversubscribed US$245 million private placement financing. This financing supports the merger between Fulcrum Therapeutics, Inc. (Nasdaq: FULC) and Slate Medicines, Inc., an all-stock transaction. The combined company will focus on advancing Slate’s pipeline, including SLTE-1009 for migraine treatment, and will trade on Nasdaq under the symbol SLTE.
Form 8K Fulcrum Therapeutics Inc For: 17 August By Investing.com
This article reports that Fulcrum Therapeutics Inc. filed a Form 8K on August 17. The filing is brief and does not provide further details within the article text. The content also includes market data and related news headlines.
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Fulcrum Therapeutics, Inc. (Nasdaq: FULC) for potential breaches of fiduciary duty related to its transaction with Slate Medicines. The investigation focuses on whether public shareholders are receiving a fair price, given that pre-merger Fulcrum stockholders will own only 5.0% of the combined company and insiders are set to receive substantial benefits. Ademi LLP is also examining whether the transaction agreement unfairly limits competing bids for Fulcrum.
Fulcrum Therapeutics (NASDAQ: FULC) backs $245M migraine venture with Slate
Fulcrum Therapeutics and Slate Medicines announced an all-stock merger, forming a new entity named Slate Medicines, Inc. that will trade on Nasdaq as "SLTE." The combined company will focus on Slate's pipeline, particularly SLTE-1009 for migraine prevention, supported by a $245 million private placement from investors led by Frazier Life Sciences. This funding is expected to support operations into 2029 as SLTE-1009 advances through clinical trials.
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Fulcrum Therapeutics, Inc. (Nasdaq: FULC) regarding its recently announced transaction with Slate Medicines, suspecting possible breaches of fiduciary duty. Under the merger agreement, pre-Merger Fulcrum stockholders are expected to own only 5.0% of the combined company, with Slate stockholders owning 95.0%. The investigation focuses on whether Fulcrum's board is fulfilling its fiduciary duties to shareholders given the low ownership percentage for existing shareholders and a significant penalty if Fulcrum accepts a competing bid.
Fulcrum Therapeutics shuts down, reverse-merges with N.C. biotech Slate
Fulcrum Therapeutics, which previously cut 85% of its workforce after discontinuing its sickle cell disease program, is undergoing a reverse merger with North Carolina-based Slate Medicines. The merger is anticipated to finalize in the fourth quarter of the year. Fulcrum is currently located at 26 Landsdowne St., occupying significant office and laboratory space.
Kaplan Fox Alerts Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Possible Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program for sickle cell disease. This decision followed heightened FDA concerns regarding the drug's benefit-risk profile due to malignancy risks associated with PRC2 inhibitors, leading to a significant 51.09% stock price decline on June 2, 2026. Investors who suffered losses are encouraged to contact Kaplan Fox for more information on the investigation.
Fulcrum Therapeutics stock rises on Slate Medicines merger deal
Fulcrum Therapeutics Inc (NASDAQ:FULC) shares rose after announcing a definitive agreement to merge with Slate Medicines Inc in an all-stock transaction. The combined company, to be named Slate Medicines, will focus on advancing migraine therapeutics and secured an oversubscribed private placement of $245 million to fund operations into 2029. The merger is expected to close in Q4 2026, with Fulcrum stockholders owning 5.0% of the combined entity.
Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal
Fulcrum Therapeutics is merging with Slate Medicines, a privately held migraine-focused biotech company, in an all-stock transaction valued at $245 million, expected to close in Q4 2026. The combined entity will be renamed Slate Medicines and trade under the Nasdaq ticker SLTE. This deal includes a private placement, a special cash dividend for pre-merger Fulcrum shareholders, and is projected to provide the new company with operational funding until 2029, focusing on Slate's lead migraine drug candidates, SLTE-1009 and SLTE-2100.
Fulcrum to merge with Slate in all-stock deal after drug setback
Fulcrum Therapeutics announced an all-stock merger with privately held Slate Medicines following the discontinuation of its lead drug candidate. The combined company will operate as Slate Medicines, trading under the ticker "SLTE" on Nasdaq, and gains access to Slate's experimental migraine drug, SLTE-1009. The deal includes a $245 million private placement, expected to fund operations into 2029 and advance its pipeline.
Fulcrum (NASDAQ: FULC) plans special cash payout in Slate merger
Fulcrum Therapeutics (NASDAQ: FULC) and Slate Medicines have announced an all-stock merger to create a combined company focused on migraine therapeutics, to be renamed Slate Medicines, Inc. and trade under the symbol SLTE. The merger includes a $245 million private placement for Slate, and Fulcrum stockholders are expected to receive a special cash dividend from approximately $270 million of additional cash at closing, contributing $20.3 million net cash for a 5% ownership stake in the new entity. The combined company's pipeline includes lead candidate SLTE-1009 for migraine prevention, with clinical trials anticipated through 2027, and is expected to have cash runway into 2029.
Fulcrum Therapeutics to Merge With Slate Medicines in Stock Deal Backed by $245 Million Financing
Fulcrum Therapeutics has announced a stock-for-stock merger with Slate Medicines, supported by a $245 million private placement. Upon closing, current Slate holders will own a majority stake, while Fulcrum plans a significant cash dividend to its stockholders, a reverse stock split, and a name change to Slate Medicines. The deal, which includes various support and lock-up agreements, is subject to customary approvals and conditions.
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies
Fulcrum Therapeutics and Slate Medicines have announced a definitive merger agreement to combine in an all-stock transaction. The combined entity, to be named Slate Medicines, Inc., will focus on advancing Slate's pipeline of next-generation migraine therapeutics, including SLTE-1009, a clinical-stage subcutaneous anti-PACAP/VIP monoclonal antibody. The merger is supported by a concurrent oversubscribed private placement of $245 million, expected to fund operations into 2029 and advance their lead product through Phase 1 and Phase 2 studies.
Therapeutics, Inc. (FULC) RA Capital group now reports 0.0% stake
RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. have filed an amended Schedule 13G/A for Fulcrum Therapeutics, Inc. (FULC). As of June 30, 2026, the group collectively beneficially owned 0 shares, representing 0.0% of the common stock. This filing indicates they no longer hold significant voting or dispositive power over the company's shares.
Fulcrum Therapeutics (FULC) investor group reduces reported ownership to 0%
An investor group comprising TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu has filed an amended Schedule 13G/A, reporting that their beneficial ownership of Fulcrum Therapeutics (FULC) common stock has been reduced to 0%. The filing indicates they no longer hold any shares and affirm ownership of 5% or less of the outstanding class. This change reflects no sole or shared voting or dispositive power over Fulcrum shares by the reporting persons.
Kaplan Fox Investigates Fulcrum Therapeutics After 51% Stock Plunge Following Pociredir Program Halt
Kaplan Fox & Kilsheimer LLP has initiated an investigation into Fulcrum Therapeutics (NASDAQ: FULC) following a 51% stock drop. The plunge occurred after Fulcrum unexpectedly halted its pociredir program for sickle cell disease due to FDA concerns over its benefit-risk balance. The investigation will examine whether Fulcrum adequately informed investors about the drug's regulatory and safety risks.
Assenagon Asset Management S.A. Has $3.06 Million Position in Fulcrum Therapeutics, Inc. $FULC
Assenagon Asset Management S.A. reduced its stake in Fulcrum Therapeutics (NASDAQ:FULC) by 30% in the second quarter, selling 358,669 shares and retaining 835,204 shares valued at $3.06 million. The company's shares opened at $3.71, near its 12-month low, and it reported a quarterly loss of $0.34 per share, missing analyst expectations. Several analysts have downgraded the stock to "hold" or "neutral" ratings, with a consensus "Reduce" rating and an average price target of $8.20.
Fulcrum Therapeutics, Inc. Appoints Alan Musso as Principal Accounting Officer, Effective August 7, 2026
Fulcrum Therapeutics, Inc. announced the appointment of Alan Musso as Principal Accounting Officer, effective August 7, 2026. Musso, who currently serves as Fulcrum's chief financial officer and principal financial officer, takes on this additional role following Mr. Tourangeau's departure. The change was communicated on August 9, 2026.
Fulcrum Therapeutics stock plunges 51% after FD...
Fulcrum Therapeutics' stock plummeted 51% after the FDA halted development of its sickle cell disease drug, pociredir, due to serious safety concerns. The FDA's decision, prompted by malignancy risks linked to similar drugs, effectively ends clinical development for pociredir, significantly impacting Fulcrum's future. This severe drop in stock price has led to a securities investigation by Kaplan Fox & Kilsheimer LLP.
Form 8K Fulcrum Therapeutics Inc For: 10 August By Investing.com
This article announces that Fulcrum Therapeutics Inc. filed a Form 8K on August 10th. The filing is a standard corporate disclosure that typically reports significant events relevant to shareholders. The brief piece is published by Investing.com, a financial markets news outlet.
Fulcrum Therapeutics appoints Alan Musso as principal accounting officer
Fulcrum Therapeutics announced that Alan Musso, its current chief financial officer, has been appointed to the additional role of principal accounting officer, effective August 7, 2026. This appointment follows the departure of Greg Tourangeau from the Vice President, Finance and principal accounting officer position. Musso will not receive additional compensation for this expanded role, and the company confirmed no conflicts of interest.
BofA Securities Maintains Fulcrum Therapeutics(FULC.US) With Sell Rating, Maintains Target Price $3
BofA Securities has maintained its Sell rating on Fulcrum Therapeutics (FULC.US) and kept its target price at $3. This indicates a continued bearish outlook from the firm regarding the company's stock performance.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Reduce" from Analysts
Fulcrum Therapeutics (NASDAQ:FULC) has received a consensus "Reduce" recommendation from analysts, with an average 12-month price target of $8.20. Several firms recently downgraded the stock and set lower price targets. This comes as the company missed quarterly earnings expectations and its shares remain significantly below their 52-week high.
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (FULC) Who Suffered Losses to Contact the Firm Regarding a Securities Investigation
Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company discontinued its pociredir program for sickle cell disease. The discontinuation followed heightened FDA concerns about the drug's benefit-risk profile due to malignancy risks associated with its class of drugs. This news led to a significant 51.09% drop in Fulcrum Therapeutics' stock price, prompting the firm to encourage affected investors to contact them.
Fulcrum Therapeutics (FULC) Stock Sees Modest Fair Value Lift After Pociredir Exit
Fulcrum Therapeutics (FULC) has seen a modest increase in its Fair Value estimate from US$5.43 to US$5.83 per share, according to Simply Wall St. This adjustment follows the company's decision to discontinue its drug pociredir, leading to a shift in analyst focus towards cash preservation, restructuring, and exploring new options. Analysts have provided mixed sentiments, with some highlighting the company's cash-rich balance sheet and others expressing caution due to the lack of a clear pipeline and FDA concerns regarding the PRC2 inhibitor class.
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm Regarding Potential Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program due to FDA concerns about malignancy risk. This news led to a significant 51.09% drop in Fulcrum Therapeutics' stock price on June 2, 2026. The firm is encouraging investors who suffered losses to contact them for more information regarding the investigation.
Bank of America (NYSE: BAC) reports 6.7% holding in Fulcrum Therapeutics (FULC)
Bank of America Corporation, through its wholly-owned subsidiaries, has reported a beneficial ownership of 6.7% in Fulcrum Therapeutics, Inc. This stake, amounting to 4,468,123 shares of common stock, is based on Fulcrum Therapeutics' reported 66,633,321 shares outstanding as of April 20, 2026. The filing indicates that Bank of America and its subsidiaries hold shared voting and shared dispositive power over these shares, with no sole voting or dispositive power.
Fulcrum Therapeutics, Inc. 2Q 2026: Net loss $(26.2M), EPS $(0.34) — 10-Q Summary
Fulcrum Therapeutics, Inc. reported a significant net loss of $(26.2M) and diluted EPS of $(0.34) for 2Q 2026, widening from the previous year, with no revenue generated. The company discontinued its sickle cell disease program, reduced its workforce by 85%, and initiated a strategic review including potential M&A or asset sales. Fulcrum has ceased R&D activities and anticipates near-term charges related to restructuring and advisory fees as it winds down operations.
Truist Financial Downgrades Fulcrum Therapeutics(FULC.US) to Hold Rating, Cuts Target Price to $4
Truist Financial has downgraded Fulcrum Therapeutics (FULC.US) to a Hold rating from a Buy rating, citing increased risk in their FA/FSHD programs. The firm has also significantly cut its price target for FULC.US from $15 to $4. This adjustment reflects a more cautious outlook on the company's prospects.
